- Celanese Corp (NYSE:CE) has received a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.
- CE expects the project to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
- Through this grant, Celanese will provide critical research and development activities to facilitate and accelerate access to long-acting contraceptive options.
- “The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe,” commented Laura Brand, VP of the Celanese medical and pharmaceutical business.
- Price Action: CE shares are trading lower by 0.04% at $115.95 on the last check Wednesday.
Rhythm Pharmaceuticals Q4 EPS $(0.75) Beats $(0.81) Estimate, Sales $8.79 Miss $7.03M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.85) per share
